<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>minutemed.ai ‚Äî Simplified Paper Summaries</title>
  <meta name="description" content="MinuteMed.ai: med-focused summaries of scientific papers with Beginner, Medium, and Pro reading levels." />

  <style>
    :root{
      --bg:#0b0f14;
      --panel:#111823;
      --panel2:#0f1620;
      --text:#e6edf3;
      --muted:#9fb0c0;
      --border:#233143;
      --accent:#7dd3fc;
      --good:#86efac;
      --warn:#fde68a;
      --bad:#fca5a5;
      --radius:16px;
      --shadow: 0 10px 30px rgba(0,0,0,.35);
      --max: 1180px;
    }

    *{box-sizing:border-box}
    body{
      margin:0;
      font-family: ui-sans-serif, system-ui, -apple-system, Segoe UI, Roboto, Helvetica, Arial, "Apple Color Emoji","Segoe UI Emoji";
      background:
        radial-gradient(1200px 650px at 15% 0%, rgba(125,211,252,.14), transparent 60%),
        radial-gradient(900px 600px at 85% 10%, rgba(134,239,172,.10), transparent 55%),
        var(--bg);
      color:var(--text);
      line-height:1.55;
    }
    a{color:var(--accent); text-decoration:none}
    a:hover{text-decoration:underline}
    .container{max-width:var(--max); margin:0 auto; padding:22px}

    header{
      position:sticky; top:0; z-index:20;
      backdrop-filter: blur(10px);
      background: rgba(11,15,20,.65);
      border-bottom:1px solid rgba(35,49,67,.6);
    }
    .topbar{
      max-width:var(--max);
      margin:0 auto;
      padding:14px 22px;
      display:flex; gap:12px; align-items:center; justify-content:space-between;
    }
    .brand{display:flex; align-items:center; gap:10px; font-weight:850; letter-spacing:.2px}
    .logo{
      width:36px; height:36px; border-radius:12px;
      background: linear-gradient(135deg, rgba(125,211,252,.95), rgba(134,239,172,.9));
      box-shadow: 0 10px 24px rgba(125,211,252,.15);
    }
    .brand small{
      display:block;
      font-weight:600;
      color:var(--muted);
      letter-spacing:0;
      margin-top:2px;
      font-size:12px;
    }
    .search{
      flex:1; max-width:600px;
      display:flex; gap:10px; align-items:center;
      background: rgba(17,24,35,.9);
      border:1px solid var(--border);
      padding:10px 12px; border-radius:999px;
    }
    .search input{
      width:100%; background:transparent; border:0; outline:0; color:var(--text);
      font-size:14px;
    }
    .chip{
      display:inline-flex; align-items:center; gap:8px;
      padding:6px 10px; border:1px solid var(--border);
      border-radius:999px; color:var(--muted); font-size:12px;
      background: rgba(17,24,35,.75);
      white-space:nowrap;
    }
    .btn{
      padding:10px 12px; border-radius:14px;
      border:1px solid var(--border);
      background: rgba(17,24,35,.9);
      color:var(--text);
      cursor:pointer;
    }
    .btn:hover{border-color:#335074}
    @media (max-width: 980px){
      .topbar{flex-wrap:wrap}
      .search{order:3; flex-basis:100%; max-width:none}
    }

    /* Layout */
    .grid{
      display:grid; gap:18px;
      grid-template-columns: 1.22fr .78fr;
      align-items:start;
    }
    @media (max-width: 980px){ .grid{grid-template-columns: 1fr} }

    /* Cards */
    .card{
      background: linear-gradient(180deg, rgba(17,24,35,.95), rgba(15,22,32,.95));
      border:1px solid var(--border);
      border-radius: var(--radius);
      box-shadow: var(--shadow);
      overflow:hidden;
    }
    .pad{padding:18px}
    .divider{height:1px; background:rgba(35,49,67,.9); margin:14px 0}

    /* Headings */
    .h1{font-size:22px; line-height:1.2; margin:0 0 10px; letter-spacing:.2px}
    .meta{display:flex; flex-wrap:wrap; gap:10px; color:var(--muted); font-size:13px}
    .meta span{display:inline-flex; gap:6px; align-items:center}
    .section h2{
      font-size:13px; letter-spacing:.15em; text-transform:uppercase;
      color:var(--muted);
      margin:0 0 10px;
    }

    /* Pills / badges */
    .pill{
      display:inline-flex; align-items:center; gap:8px;
      padding:7px 10px; border-radius:999px;
      border:1px solid var(--border);
      background: rgba(17,24,35,.65);
      font-size:12px; color:var(--muted);
    }
    .badge{
      display:inline-flex; align-items:center;
      padding:5px 9px; border-radius:999px;
      border:1px solid var(--border);
      background: rgba(17,24,35,.65);
      font-size:12px; color:var(--muted);
    }
    .badge.good{color:var(--good)}
    .badge.warn{color:var(--warn)}
    .badge.bad{color:var(--bad)}

    /* Tabs */
    .tabs{
      display:flex; gap:8px; flex-wrap:wrap;
      border:1px solid var(--border);
      background: rgba(17,24,35,.55);
      padding:8px;
      border-radius: 999px;
      width:fit-content;
    }
    .tab{
      border:1px solid transparent;
      background: transparent;
      color: var(--muted);
      padding:8px 12px;
      border-radius:999px;
      cursor:pointer;
      font-weight:700;
      font-size:13px;
    }
    .tab[aria-selected="true"]{
      background: rgba(125,211,252,.12);
      color: var(--text);
      border-color: rgba(125,211,252,.28);
    }
    .tab:focus{
      outline:2px solid rgba(125,211,252,.35);
      outline-offset:2px;
    }

    /* Lists */
    .list{margin:0; padding-left:18px}
    .list li{margin:6px 0}
    .small{font-size:13px; color:var(--muted)}
    .kpi{
      display:grid; gap:10px;
      grid-template-columns: repeat(3, minmax(0, 1fr));
      margin-top:12px;
    }
    @media (max-width: 650px){ .kpi{grid-template-columns: 1fr} }
    .kpi .box{
      border:1px solid var(--border);
      background: rgba(17,24,35,.65);
      border-radius: 14px;
      padding:12px;
    }
    .kpi .label{color:var(--muted); font-size:12px}
    .kpi .value{font-size:16px; font-weight:850; margin-top:4px}

    /* Paper list items */
    .paperGrid{display:grid; gap:12px}
    .paperItem{
      border:1px solid var(--border);
      background: rgba(17,24,35,.65);
      border-radius: 14px;
      padding:14px;
      cursor:pointer;
      transition: transform .08s ease, border-color .08s ease;
    }
    .paperItem:hover{transform: translateY(-1px); border-color:#335074}
    .paperTitle{margin:0 0 6px; font-size:15px; line-height:1.25}
    .paperSub{margin:0; color:var(--muted); font-size:13px}
    .row{display:flex; gap:8px; flex-wrap:wrap; margin-top:10px}

    /* Views */
    .hidden{display:none !important}

    /* Sidebar */
    .paperlist{display:grid; gap:12px}
    .paperitem{
      border:1px solid var(--border);
      background: rgba(17,24,35,.65);
      border-radius: 14px;
      padding:12px;
    }
    .paperitem h3{margin:0 0 6px; font-size:14px}
    .paperitem p{margin:0; color:var(--muted); font-size:13px}

    footer{padding:26px 0; color:var(--muted); font-size:13px}
    .kbd{
      font-family: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, "Liberation Mono", "Courier New", monospace;
      border:1px solid var(--border);
      background: rgba(17,24,35,.65);
      padding:2px 7px;
      border-radius:8px;
      font-size:12px;
      color:var(--muted);
    }
  </style>
</head>

<body>
<header>
  <div class="topbar">
    <div class="brand" role="banner">
      <div class="logo" aria-hidden="true"></div>
      <div>
        minutemed.ai
        <small>Paper ‚Üí practice, in minutes</small>
      </div>
    </div>

    <div class="search" role="search" aria-label="Search papers">
      <span class="small" aria-hidden="true">üîé</span>
      <input id="searchInput" type="search" placeholder="Search papers, conditions, drugs‚Ä¶ (static demo)" />
      <span class="chip">Try: ‚Äúdonanemab‚Äù</span>
    </div>

    <button id="homeBtn" class="btn" type="button" title="Back to paper list">Home</button>
  </div>
</header>

<main class="container">
  <div class="grid">
    <!-- MAIN -->
    <section aria-label="Main content">
      <!-- HOME: list of relevant papers -->
      <article id="homeView" class="card section">
        <div class="pad">
          <h2>Currently relevant</h2>
          <p class="small" style="margin:0 0 12px;">
            Click a paper to open it, then choose your level: <strong>Beginner</strong>, <strong>Medium</strong>, or <strong>Pro</strong>.
          </p>

          <div class="divider"></div>

          <div id="paperList" class="paperGrid" aria-label="Paper list"></div>
        </div>
      </article>

      <!-- DETAIL: paper page -->
      <article id="detailView" class="card hidden" aria-label="Paper detail">
        <div class="pad">
          <div style="display:flex; justify-content:space-between; gap:12px; flex-wrap:wrap; align-items:flex-start;">
            <div>
              <h1 id="paperTitle" class="h1"></h1>
              <div id="paperMeta" class="meta"></div>
              <div id="paperTags" class="row"></div>
            </div>
            <div class="row">
              <span id="paperStatus" class="badge good">‚óè Relevant</span>
              <span id="paperDate" class="badge">Updated: ‚Äî</span>
            </div>
          </div>

          <div class="divider"></div>

          <div class="section">
            <h2>Choose your level</h2>
            <div class="tabs" role="tablist" aria-label="Knowledge level">
              <button class="tab" role="tab" id="tab-beginner" aria-controls="panel-beginner" aria-selected="true" data-level="beginner">Beginner</button>
              <button class="tab" role="tab" id="tab-medium" aria-controls="panel-medium" aria-selected="false" data-level="medium">Medium</button>
              <button class="tab" role="tab" id="tab-pro" aria-controls="panel-pro" aria-selected="false" data-level="pro">Pro</button>
            </div>
            <p class="small" style="margin:12px 0 0;">
              Keyboard: <span class="kbd">1</span> Beginner, <span class="kbd">2</span> Medium, <span class="kbd">3</span> Pro, <span class="kbd">Esc</span> back to list.
            </p>
          </div>

          <div class="divider"></div>

          <!-- Panels (content is rendered dynamically, headings remain consistent) -->
          <div id="panel-beginner" class="section" role="tabpanel" aria-labelledby="tab-beginner" data-panel="beginner"></div>
          <div id="panel-medium" class="section hidden" role="tabpanel" aria-labelledby="tab-medium" data-panel="medium"></div>
          <div id="panel-pro" class="section hidden" role="tabpanel" aria-labelledby="tab-pro" data-panel="pro"></div>
        </div>
      </article>
    </section>

    <!-- SIDEBAR -->
    <aside aria-label="Sidebar">
      <div class="card">
        <div class="pad section">
          <h2>How to use MinuteMed</h2>
          <ul class="list">
            <li><strong>Home</strong> shows what‚Äôs hot right now (papers people are actually talking about).</li>
            <li>Click a paper ‚Üí pick your level ‚Üí skim the same headings every time.</li>
            <li>Beginner = clinical story. Medium = journal club ready. Pro = mechanism + critique.</li>
          </ul>

          <div class="divider"></div>

          <h2>Consistent headings</h2>
          <p class="small" style="margin:0;">
            Every level uses the same structure: <strong>TL;DR</strong>, <strong>The Big Question</strong>, <strong>Methods</strong>, <strong>Results</strong>, <strong>Limitations</strong>, <strong>Discussion</strong>, <strong>Citations</strong>.
          </p>
        </div>
      </div>

      <div class="card" style="margin-top:18px;">
        <div class="pad section">
          <h2>Up next</h2>
          <div class="paperlist">
            <div class="paperitem">
              <h3>Feature idea: ‚ÄúWhy this matters‚Äù cards</h3>
              <p>Auto-generate clinical implications + who this applies to.</p>
            </div>
            <div class="paperitem">
              <h3>Feature idea: ‚ÄúMechanism map‚Äù</h3>
              <p>One diagram per drug/paper (pathway-first).</p>
            </div>
            <div class="paperitem">
              <h3>Feature idea: ‚ÄúCompare trials‚Äù</h3>
              <p>Same endpoint, different papers ‚Üí side-by-side.</p>
            </div>
          </div>
        </div>
      </div>
    </aside>
  </div>

  <footer class="container" style="padding-left:0; padding-right:0;">
    <div class="divider"></div>
    <p style="margin:0;">
      ¬© <span id="year"></span> minutemed.ai ‚Äî Static demo layout (list ‚Üí paper ‚Üí level).
    </p>
  </footer>
</main>

<script>
  // --- Data: 4 currently relevant, widely discussed papers (static examples) ---
  // Each paper contains the same section keys per level, ensuring consistent headings.
  const PAPERS = [
    {
      id: "nejm-immune-evasive-islets-2025",
      relevance: "Hot",
      updated: "2026-02-15",
      title: "Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression",
      journal: "N Engl J Med",
      year: "2025",
      design: "Case report (first-in-human, gene-edited donor islets)",
      sample: "n = 1",
      area: "Endocrinology ‚Ä¢ Transplant ‚Ä¢ Gene editing",
      tags: ["Type 1 Diabetes", "CRISPR/Cas12b", "Immune evasion", "Islet transplant"],
      evidenceBadge: { tone:"warn", text:"Evidence: Early (n=1)" },
      links: [
        { label: "DOI", url: "https://doi.org/10.1056/NEJMoa2503822" },
        { label: "PubMed", url: "https://pubmed.ncbi.nlm.nih.gov/40757665/" },
        { label: "ClinicalTrials.gov", url: "https://clinicaltrials.gov/study/NCT06239636" }
      ],
      summaries: {
        beginner: {
          kpi: [
            { label:"What problem?", value:"T1D needs insulin; transplants usually need immune-suppressing meds" },
            { label:"What‚Äôs new?", value:"Gene-edited donor islet cells to avoid rejection" },
            { label:"What happened?", value:"Cells worked 12 weeks without immunosuppression" }
          ],
          tldr: [
            "This report describes a person with type 1 diabetes who received donor insulin-producing cells that were gene-edited to help them ‚Äúhide‚Äù from the immune system.",
            "The patient did not take anti-rejection medications, and the transplanted cells still showed glucose-responsive insulin secretion at 12 weeks."
          ],
          bigQuestion: [
            "Can we transplant insulin-producing cells without lifelong immunosuppression?",
            "If we can avoid immune rejection safely, cell therapy for type 1 diabetes becomes much more realistic."
          ],
          methods: [
            "Donor islet cells were genetically modified using CRISPR/Cas12b plus additional engineering to reduce immune recognition.",
            "Cells were implanted into forearm muscle (not the usual portal vein route).",
            "They monitored immune response and insulin secretion using C-peptide and glucose responsiveness."
          ],
          results: [
            "At 12 weeks, there was no detected immune response against the edited cells.",
            "C-peptide suggested stable, glucose-responsive insulin secretion.",
            "No serious adverse events were reported in this short follow-up."
          ],
          limitations: [
            "This is one patient (n=1), so we can‚Äôt assume it will work for everyone.",
            "Short follow-up: we don‚Äôt yet know durability (months/years) or rare safety issues.",
            "Type 1 diabetes includes autoimmunity‚Äîlong-term immune escape has to be proven safe."
          ],
          discussion: [
            "If this lasts years, how might it change the standard of care for type 1 diabetes?",
            "What‚Äôs the best transplant site: forearm muscle vs liver (portal vein) vs elsewhere?",
            "What is the tradeoff between immune evasion and safety (e.g., surveillance for abnormal cell growth)?"
          ],
          citations: [
            "Carlsson PO, et al. N Engl J Med. 2025;393(9):887‚Äì894. doi:10.1056/NEJMoa2503822."
          ]
        },
        medium: {
          kpi: [
            { label:"Design", value:"First-in-human case report" },
            { label:"Mechanism", value:"Reduce HLA visibility + increase immune 'don‚Äôt eat me' signaling" },
            { label:"Readout", value:"C-peptide + immune reactivity over 12 weeks" }
          ],
          tldr: [
            "A gene-edited allogeneic islet product was transplanted into a person with long-standing T1D without immunosuppression, showing glucose-responsive insulin secretion at 12 weeks.",
            "This is a proof-of-concept for ‚Äúhypoimmune‚Äù beta-cell replacement, with the main question now being durability, scalability, and long-term safety."
          ],
          bigQuestion: [
            "Can genetic engineering of donor islet cells enable functional engraftment without systemic immunosuppression?",
            "If yes, beta-cell replacement could shift from niche transplant medicine toward broader clinical adoption."
          ],
          methods: [
            "Allogeneic donor islet cells were edited (CRISPR/Cas12b) and further engineered to reduce alloimmune recognition; product transplanted intramuscularly (forearm).",
            "No immunosuppressive drugs were administered.",
            "Primary assessments: immune response against graft + biochemical evidence of insulin secretion (C-peptide), including glucose responsiveness."
          ],
          results: [
            "No detected immune response against the gene-edited cells at 12 weeks.",
            "C-peptide remained stable and glucose-responsive, consistent with graft function.",
            "Four adverse events occurred; none were serious or related to the intervention (short observation window)."
          ],
          limitations: [
            "Single patient; uncontrolled design; limited inference on efficacy magnitude.",
            "Short follow-up (12 weeks reported in abstract context).",
            "Generalizability: intramuscular site, product manufacturing, and immune profile vary across patients."
          ],
          discussion: [
            "What monitoring should be required for long-term immune-evasive grafts (imaging, biomarkers, safety switches)?",
            "How do we separate alloimmune vs autoimmune failure modes in T1D over time?",
            "What endpoints matter most in future trials: insulin independence, A1c, time-in-range, hypoglycemia burden?"
          ],
          citations: [
            "Carlsson PO, et al. N Engl J Med. 2025;393(9):887‚Äì894. doi:10.1056/NEJMoa2503822."
          ]
        },
        pro: {
          kpi: [
            { label:"Intervention", value:"Hypoimmune allogeneic islet graft (edited + engineered)" },
            { label:"Key risk", value:"Durability vs immune escape tradeoffs (safety + tumor surveillance)" },
            { label:"Next step", value:"Dose, durability, reproducibility in cohorts" }
          ],
          tldr: [
            "This first-in-human report demonstrates short-term functional persistence of an engineered hypoimmune allogeneic islet graft without immunosuppression, with biochemical evidence of glucose-responsive insulin secretion.",
            "Mechanistically, the approach aims to blunt antigen presentation/recognition while adding pro-survival immune-modulatory signaling; clinically, it reframes beta-cell replacement around engineered immune compatibility rather than systemic suppression."
          ],
          bigQuestion: [
            "Can we create a clinically durable, scalable beta-cell replacement platform that is immune evasive yet still safe and controllable in vivo?",
            "How do we design future trials to distinguish engraftment success, immune escape, and long-term off-target risks?"
          ],
          methods: [
            "Gene editing (CRISPR/Cas12b) and transduction-based engineering to reduce rejection susceptibility, followed by intramuscular transplantation.",
            "No immunosuppression; serial immune surveillance and functional assays (C-peptide, glucose responsiveness).",
            "Trial registration and structured AE capture (proof-of-concept clinical translation)."
          ],
          results: [
            "Short-term engraftment with maintained glucose-responsive secretion and no detectable immune response signals at 12 weeks.",
            "AE profile in this timeframe lacked serious events attributable to the product, but exposure is minimal and underpowered for safety."
          ],
          limitations: [
            "n=1; heavy selection/measurement context; absence of comparator; interpret as translational feasibility signal only.",
            "Durability unknown: immune pressure, inflammatory microenvironment, and autoimmunity may emerge over months/years.",
            "Safety architecture not established in this summary: long-term immune evasion raises surveillance concerns (infection, malignancy escape) unless kill-switch or control systems are implemented."
          ],
          discussion: [
            "What is the optimal engineering stack: antigen presentation reduction vs checkpoint modulation vs physical encapsulation?",
            "What trial design best answers: intramuscular vs intraportal site, dose-response, and standardized metabolic endpoints?",
            "How should regulatory frameworks treat long-lived immune-evasive cell grafts (longitudinal registries, mandated safety monitoring)?"
          ],
          citations: [
            "Carlsson PO, et al. N Engl J Med. 2025;393(9):887‚Äì894. doi:10.1056/NEJMoa2503822."
          ]
        }
      }
    },

    {
      id: "tjpad-donanemab-lte-2025",
      relevance: "Trending",
      updated: "2026-02-15",
      title: "Donanemab in early symptomatic Alzheimer‚Äôs disease: TRAILBLAZER-ALZ 2 long-term extension",
      journal: "J Prev Alzheimers Dis",
      year: "2026 (Epub 2025)",
      design: "Long-term extension (phase 3 program)",
      sample: "3-year outcomes (extension + external controls)",
      area: "Neurology ‚Ä¢ Alzheimer‚Äôs",
      tags: ["Alzheimer‚Äôs", "Anti-amyloid", "Disease-modifying therapy", "Long-term outcomes"],
      evidenceBadge: { tone:"good", text:"Evidence: Phase 3 program" },
      links: [
        { label: "DOI", url: "https://doi.org/10.1016/j.tjpad.2025.100446" },
        { label: "PubMed", url: "https://pubmed.ncbi.nlm.nih.gov/41330788/" }
      ],
      summaries: {
        beginner: {
          kpi: [
            { label:"What problem?", value:"Alzheimer‚Äôs slowly worsens memory and daily function" },
            { label:"What did they test?", value:"A drug that removes amyloid plaques (donanemab)" },
            { label:"Main idea", value:"Earlier treatment may help more over time" }
          ],
          tldr: [
            "This study followed people who previously participated in a major donanemab trial and looked at how they did over about 3 years.",
            "People who started donanemab earlier tended to decline more slowly than similar people who didn‚Äôt receive the drug in the same way."
          ],
          bigQuestion: [
            "Does starting donanemab earlier lead to bigger long-term benefits in Alzheimer‚Äôs?",
            "Can treatment be limited in duration (stop after amyloid clears) while keeping benefits?"
          ],
          methods: [
            "People who finished the original placebo-controlled phase could enter a long-term extension.",
            "Some started donanemab early; others started later (after placebo).",
            "They compared outcomes over time and also used an external comparison group from an Alzheimer‚Äôs research cohort."
          ],
          results: [
            "Over 3 years, early-start participants showed slower worsening on standard dementia scales compared with the external control group.",
            "Many participants reached very low amyloid levels (‚Äúamyloid clearance‚Äù).",
            "Safety signals did not show new surprises compared with what is already known for this type of therapy."
          ],
          limitations: [
            "Extensions and external comparisons are trickier than a clean randomized trial.",
            "Benefits are usually modest and must be weighed against risks (like MRI changes/ARIA in anti-amyloid drugs).",
            "Real-world results can differ depending on patient selection and monitoring."
          ],
          discussion: [
            "Who benefits most‚Äîpeople with lower tau burden or earlier disease stages?",
            "How often should patients be monitored (MRI schedule, symptoms)?",
            "What does ‚Äúlimited-duration dosing‚Äù mean for cost and safety?"
          ],
          citations: [
            "Zimmer JA, et al. J Prev Alzheimers Dis. 2026;13(2):100446. Epub 2025 Dec 1. doi:10.1016/j.tjpad.2025.100446."
          ]
        },
        medium: {
          kpi: [
            { label:"Design", value:"LTE + early-start vs delayed-start + external cohort" },
            { label:"Endpoint", value:"CDR-SB trajectory (3-year)" },
            { label:"Signal", value:"Increasing separation favoring early start" }
          ],
          tldr: [
            "TRAILBLAZER-ALZ 2 long-term extension data suggest accumulating clinical benefit over ~3 years in early-start donanemab participants, with substantial amyloid clearance and no new safety signals versus the established profile.",
            "Interpretation requires caution because long-term extensions and external controls are not equivalent to randomized comparisons."
          ],
          bigQuestion: [
            "Does early initiation of anti-amyloid therapy produce greater long-horizon clinical separation, and can dosing be time-limited after biomarker-defined amyloid clearance?",
            "How do biomarker trajectories (amyloid/tau) map onto clinical endpoints over multi-year windows?"
          ],
          methods: [
            "Participants completing the placebo-controlled period entered a double-blind extension; delayed-start participants began donanemab in LTE.",
            "Participants meeting amyloid treatment-course completion criteria could be switched to placebo (limited-duration dosing framework).",
            "External control cohort derived from ADNI with weighting/adjustment to compare CDR-SB trajectories."
          ],
          results: [
            "Early-start participants showed slower CDR-SB progression vs weighted ADNI control over 3 years; delayed-start also showed benefit after initiating therapy.",
            "High proportion achieved amyloid clearance at ~76 weeks after starting donanemab.",
            "Modeling suggested gradual amyloid reaccumulation after stopping (biomarker durability question)."
          ],
          limitations: [
            "External control comparisons are vulnerable to residual confounding despite weighting.",
            "LTE populations can differ from original randomized population (attrition/selection).",
            "Clinical effect size and risk-benefit must be framed for patients and caregivers (monitoring burden, ARIA risk)."
          ],
          discussion: [
            "How should clinicians choose candidates (tau, comorbidity, anticoagulation, MRI microbleeds)?",
            "What is the optimal stop/restart strategy if amyloid reaccumulates?",
            "Which endpoints best capture ‚Äúmeaningful‚Äù change for patients over years?"
          ],
          citations: [
            "Zimmer JA, et al. J Prev Alzheimers Dis. 2026;13(2):100446. Epub 2025 Dec 1. doi:10.1016/j.tjpad.2025.100446."
          ]
        },
        pro: {
          kpi: [
            { label:"Framework", value:"Biomarker-guided, limited-duration dosing" },
            { label:"Core critique", value:"LTE + external controls ‚â† RCT inference" },
            { label:"Clinical hinge", value:"Risk-benefit + monitoring logistics" }
          ],
          tldr: [
            "Three-year extension data from TRAILBLAZER-ALZ 2 support a biomarker-guided model where substantial amyloid clearance can be achieved and clinical trajectories may continue to separate with earlier initiation, while maintaining a consistent safety profile.",
            "However, analytic dependence on external controls and the LTE structure limits causal inference; the key translational question is how to operationalize candidate selection and dosing cadence to optimize benefit and minimize ARIA-related harms."
          ],
          bigQuestion: [
            "Can anti-amyloid therapy be deployed as a time-limited, biomarker-driven intervention with durable clinical benefit, and what biomarker thresholds best define treatment-course completion and re-treatment triggers?",
            "How do tau stage, vascular comorbidity, and MRI risk features modulate marginal benefit?"
          ],
          methods: [
            "LTE with early-start vs delayed-start exposure patterns; protocol allowed switching to placebo after PET-defined amyloid thresholds.",
            "External comparator (ADNI) weighted to approximate treated cohort; repeated-measures modeling for CDR-SB trajectories.",
            "Safety surveillance consistent with anti-amyloid programs; evaluation of amyloid kinetics including reaccumulation modeling."
          ],
          results: [
            "Observed clinical slowing vs weighted external controls, plus evidence of clinical advantage for early-start vs delayed-start patterns.",
            "High amyloid clearance rates by PET; modeled reaccumulation suggests biomarker durability is finite and potentially measurable.",
            "No novel safety signals beyond established donanemab profile in this dataset."
          ],
          limitations: [
            "Residual confounding and informative censoring are non-trivial in LTE/external-control setups.",
            "Generalizability: trial-grade MRI/PET infrastructure and monitoring cadence may not reflect community implementation.",
            "The clinically meaningful threshold for CDR-SB change remains debated and patient-dependent."
          ],
          discussion: [
            "What is the minimal imaging/biomarker package needed to safely run limited-duration dosing in routine care?",
            "Could adaptive dosing (based on amyloid kinetics) reduce ARIA exposure while preserving benefit?",
            "How should health systems triage access: earliest disease, lowest tau, highest predicted response?"
          ],
          citations: [
            "Zimmer JA, et al. J Prev Alzheimers Dis. 2026;13(2):100446. Epub 2025 Dec 1. doi:10.1016/j.tjpad.2025.100446."
          ]
        }
      }
    },

    {
      id: "nejm-tirzepatide-osa-2024",
      relevance: "Relevant",
      updated: "2026-02-15",
      title: "Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity",
      journal: "N Engl J Med",
      year: "2024",
      design: "Two randomized trials (OSA + obesity)",
      sample: "Adults with moderate-to-severe OSA and obesity",
      area: "Pulm/Sleep ‚Ä¢ Obesity medicine",
      tags: ["OSA", "Tirzepatide", "GLP-1/GIP", "Patient-reported outcomes"],
      evidenceBadge: { tone:"good", text:"Evidence: RCTs" },
      links: [
        { label: "DOI", url: "https://doi.org/10.1056/NEJMoa2404881" }
      ],
      summaries: {
        beginner: {
          kpi: [
            { label:"What problem?", value:"Sleep apnea causes repeated breathing stops at night" },
            { label:"What did they try?", value:"A weight-loss medication (tirzepatide)" },
            { label:"What improved?", value:"Apnea severity and related symptoms" }
          ],
          tldr: [
            "These trials studied adults with obesity and obstructive sleep apnea and tested whether tirzepatide could improve sleep apnea severity.",
            "People on tirzepatide had fewer apnea events, lost weight, and reported better sleep-related outcomes compared with placebo."
          ],
          bigQuestion: [
            "If obesity drives sleep apnea, can a medication that meaningfully reduces weight also reduce apnea severity?",
            "Can patients avoid or reduce reliance on CPAP when the underlying driver improves?"
          ],
          methods: [
            "Adults with moderate-to-severe OSA and obesity were randomized to tirzepatide or placebo.",
            "They measured apnea-hypopnea index (AHI), body weight, and patient-reported outcomes.",
            "They also tracked cardiometabolic markers (like inflammation markers and blood pressure)."
          ],
          results: [
            "Tirzepatide reduced AHI and improved measures tied to oxygen drops during sleep.",
            "Weight decreased substantially, and multiple cardiometabolic markers improved.",
            "Patient-reported sleep outcomes improved, suggesting the change mattered day-to-day."
          ],
          limitations: [
            "Not everyone with OSA has obesity-driven disease; some will still need CPAP or other therapies.",
            "Long-term durability depends on maintaining weight loss.",
            "Medication side effects and access/cost can limit use."
          ],
          discussion: [
            "Which patients with OSA should be offered this first vs CPAP first vs both?",
            "How do we define success‚ÄîAHI reduction, symptoms, blood pressure, or long-term cardiovascular outcomes?",
            "What happens if the drug is stopped?"
          ],
          citations: [
            "Tirzepatide for OSA and obesity. N Engl J Med. 2024. doi:10.1056/NEJMoa2404881."
          ]
        },
        medium: {
          kpi: [
            { label:"Mechanism", value:"Weight loss + metabolic/inflammatory improvements" },
            { label:"Endpoints", value:"AHI, hypoxic burden, PROs" },
            { label:"Interpretation", value:"Treats a key driver, not all phenotypes" }
          ],
          tldr: [
            "Across two randomized trials in adults with moderate-to-severe OSA and obesity, tirzepatide reduced AHI and hypoxic burden while improving weight, inflammation markers, BP, and sleep-related patient-reported outcomes.",
            "Clinically, this supports a ‚Äòtreat-the-driver‚Äô strategy for OSA in the obesity phenotype, potentially as adjunct or alternative to device-based therapies for selected patients."
          ],
          bigQuestion: [
            "Does pharmacologic weight loss produce clinically meaningful OSA improvement (AHI + symptoms), and for whom?",
            "How should tirzepatide integrate with CPAP, mandibular devices, and lifestyle interventions?"
          ],
          methods: [
            "Randomized, placebo-controlled trials enrolling adults with obesity and moderate-to-severe OSA.",
            "Primary physiologic endpoints included AHI; secondary endpoints included weight change, hypoxic burden, hsCRP, BP, and PROs.",
            "Safety assessment included typical GI effects and discontinuation patterns."
          ],
          results: [
            "Significant AHI reduction and improvements in hypoxic burden.",
            "Substantial weight loss and favorable cardiometabolic shifts (hsCRP, systolic BP).",
            "PRO improvements suggested symptomatic benefit beyond a purely numeric endpoint."
          ],
          limitations: [
            "OSA is heterogeneous: anatomic factors and non-obesity phenotypes may have less response.",
            "Durability depends on sustained therapy and/or sustained weight loss.",
            "Comparative effectiveness vs CPAP or combination strategies needs continued study."
          ],
          discussion: [
            "What AHI and symptom thresholds justify therapy initiation or continuation?",
            "How should clinicians monitor response‚Äîrepeat sleep study vs symptoms + wearable proxies?",
            "What is the long-term cardiovascular outcome impact of treating OSA via weight-loss pharmacotherapy?"
          ],
          citations: [
            "Tirzepatide for OSA and obesity. N Engl J Med. 2024. doi:10.1056/NEJMoa2404881."
          ]
        },
        pro: {
          kpi: [
            { label:"Clinical frame", value:"OSA phenotype stratification (obesity-driven vs structural)" },
            { label:"Outcome nuance", value:"AHI vs hypoxic burden vs PROs" },
            { label:"Next step", value:"Head-to-head and CV outcomes" }
          ],
          tldr: [
            "The tirzepatide OSA trials reinforce that meaningful metabolic intervention can reduce sleep-disordered breathing severity (AHI) and physiologic stress (hypoxic burden), likely via weight loss plus downstream inflammatory/hemodynamic effects.",
            "Implementation hinges on phenotype selection, integration with standard-of-care devices, and defining clinically meaningful response beyond AHI‚Äîespecially symptom and cardiovascular risk endpoints."
          ],
          bigQuestion: [
            "Which OSA phenotypes derive the greatest marginal benefit from incretin-based pharmacotherapy, and can these agents reduce downstream cardiovascular events mediated by OSA?",
            "What is the optimal combined strategy (CPAP + pharmacotherapy) and sequence of intervention?"
          ],
          methods: [
            "Two RCTs in obesity-associated moderate-to-severe OSA; physiologic and patient-centered endpoints tracked longitudinally.",
            "Secondary analyses on biomarkers and BP contextualize systemic impact.",
            "Safety/tolerability analysis is key because adherence and discontinuation affect real-world efficacy."
          ],
          results: [
            "Robust reductions in AHI and hypoxic burden consistent with improved airway mechanics and/or reduced collapsibility pressure dynamics after weight loss.",
            "Cardiometabolic improvements align with a broader risk modification profile.",
            "PRO gains suggest functional relevance for patients, not just polysomnography changes."
          ],
          limitations: [
            "OSA is not a single disease‚Äîupper airway anatomy, loop gain, arousal threshold can modulate response independently of weight.",
            "AHI may not fully capture cardiovascular risk reduction; hypoxic burden may correlate better but remains an evolving endpoint.",
            "Longitudinal outcomes and pragmatic implementation studies are needed (access, dosing, maintenance)."
          ],
          discussion: [
            "Should hypoxic burden be a co-primary endpoint in future OSA trials?",
            "What patient selection algorithm maximizes response (BMI, neck circumference, baseline AHI, positional OSA features)?",
            "How do we model cost-effectiveness when therapy impacts multiple comorbidities simultaneously?"
          ],
          citations: [
            "Tirzepatide for OSA and obesity. N Engl J Med. 2024. doi:10.1056/NEJMoa2404881."
          ]
        }
      }
    },

    {
      id: "nejm-select-semaglutide-2023",
      relevance: "Core",
      updated: "2026-02-15",
      title: "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)",
      journal: "N Engl J Med",
      year: "2023",
      design: "Cardiovascular outcomes trial (RCT)",
      sample: "n = 17,604",
      area: "Cardiology ‚Ä¢ Obesity medicine",
      tags: ["Semaglutide", "MACE", "Obesity", "CV outcomes"],
      evidenceBadge: { tone:"good", text:"Evidence: Large CVOT" },
      links: [
        { label: "DOI", url: "https://doi.org/10.1056/NEJMoa2307563" },
        { label: "PubMed", url: "https://pubmed.ncbi.nlm.nih.gov/37952131/" }
      ],
      summaries: {
        beginner: {
          kpi: [
            { label:"What problem?", value:"Heart attacks and strokes are common in obesity" },
            { label:"What did they test?", value:"Semaglutide vs placebo in people without diabetes" },
            { label:"Key result", value:"Fewer major heart events on semaglutide" }
          ],
          tldr: [
            "This large trial tested whether semaglutide (a GLP-1 medicine) lowers heart attack and stroke risk in people with overweight/obesity who already had heart disease, even if they don‚Äôt have diabetes.",
            "Semaglutide lowered the risk of major cardiovascular events compared with placebo."
          ],
          bigQuestion: [
            "Can a weight-loss/metabolic medication directly reduce major heart events in people with obesity but no diabetes?",
            "If yes, obesity treatment becomes cardiovascular prevention, not just cosmetics."
          ],
          methods: [
            "Adults with overweight/obesity and established cardiovascular disease, without diabetes, were randomized to semaglutide or placebo.",
            "They were followed for major cardiovascular events (heart attack, stroke, cardiovascular death).",
            "They also tracked weight, side effects, and treatment discontinuation."
          ],
          results: [
            "The semaglutide group had fewer major cardiovascular events than the placebo group.",
            "Weight decreased meaningfully, and other cardiometabolic markers often improve on GLP-1 therapy.",
            "Side effects were mainly GI-related; some people stopped medication."
          ],
          limitations: [
            "These were people who already had cardiovascular disease, so it may not apply the same way to lower-risk populations.",
            "Long-term adherence matters; stopping can reduce benefits.",
            "Cost and access influence real-world impact."
          ],
          discussion: [
            "Should semaglutide be considered a cardiovascular prevention therapy in obesity?",
            "Which patients benefit most‚Äîthose with the highest baseline risk or best tolerability?",
            "How do we weigh benefits vs side effects and cost?"
          ],
          citations: [
            "Lincoff AM, et al. N Engl J Med. 2023;389:2221‚Äì2232. doi:10.1056/NEJMoa2307563."
          ]
        },
        medium: {
          kpi: [
            { label:"Design", value:"CV outcomes RCT" },
            { label:"Population", value:"CVD + overweight/obesity, no diabetes" },
            { label:"Endpoint", value:"MACE reduction" }
          ],
          tldr: [
            "SELECT demonstrated that semaglutide reduced major adverse cardiovascular events in adults with established CVD and overweight/obesity but without diabetes, positioning GLP-1 therapy as cardiometabolic risk modification beyond glycemic control.",
            "Translation requires attention to patient selection, adherence, and implementation barriers (tolerability, coverage)."
          ],
          bigQuestion: [
            "Does GLP-1‚Äìbased therapy reduce hard cardiovascular endpoints in obesity independent of diabetes status?",
            "What mechanisms drive MACE reduction: weight loss, BP/lipids, inflammation, or direct vascular effects?"
          ],
          methods: [
            "Large RCT (CVOT) randomizing high-risk adults to semaglutide vs placebo with long follow-up.",
            "Primary endpoint: composite MACE.",
            "Safety/tolerability tracked, including discontinuation and adverse event patterns."
          ],
          results: [
            "Lower MACE incidence in the semaglutide arm compared with placebo.",
            "Consistent weight reduction; multiple downstream risk factors typically improve with therapy.",
            "GI adverse effects and discontinuation are meaningful real-world considerations."
          ],
          limitations: [
            "Applies primarily to secondary prevention (already-established CVD).",
            "Efficacy depends on sustained exposure; discontinuation blunts benefit.",
            "Broader external validity depends on coverage and patient adherence."
          ],
          discussion: [
            "What‚Äôs the incremental benefit vs other cardioprotective therapies (statins, SGLT2i where indicated)?",
            "How should clinicians prioritize therapy when multiple cardiometabolic drugs compete for adherence?",
            "What biomarkers best predict responders (baseline inflammation, adiposity distribution, etc.)?"
          ],
          citations: [
            "Lincoff AM, et al. N Engl J Med. 2023;389:2221‚Äì2232. doi:10.1056/NEJMoa2307563."
          ]
        },
        pro: {
          kpi: [
            { label:"Clinical impact", value:"Obesity pharmacotherapy ‚Üí secondary CV prevention" },
            { label:"Mechanism debate", value:"Weight loss vs direct vascular effects" },
            { label:"Implementation", value:"Adherence + access determine real-world benefit" }
          ],
          tldr: [
            "SELECT redefines GLP-1 therapy as a cardiovascular risk modifier in non-diabetic obesity, demonstrating MACE reduction in a high-risk secondary prevention cohort.",
            "The mechanistic story likely integrates adiposity reduction, BP/lipid shifts, inflammatory modulation, and potential direct vascular effects; the pragmatic story is tolerability, persistence, and equitable access."
          ],
          bigQuestion: [
            "What causal pathways best explain MACE reduction with semaglutide in non-diabetic obesity, and can we stratify patients by mechanistic phenotype (inflammatory, metabolic, hemodynamic)?",
            "How should treatment be sequenced with other cardiometabolic interventions for maximal net benefit?"
          ],
          methods: [
            "CVOT design with hard endpoints and robust adjudication.",
            "Large sample enables subgroup exploration (but interpretation should remain cautious).",
            "Safety analysis highlights discontinuation dynamics that influence effectiveness."
          ],
          results: [
            "Demonstrated MACE reduction in a non-diabetic, CVD, obesity/overweight cohort.",
            "Weight and risk factor improvements provide plausible mediators; causal mediation remains complex.",
            "Adverse event profile consistent with GLP-1 class and clinically relevant for persistence."
          ],
          limitations: [
            "Generalization to primary prevention or non-CVD populations is not automatic.",
            "Effect heterogeneity may exist (age, baseline BMI, visceral adiposity, inflammatory burden), requiring careful secondary analysis.",
            "Real-world impact may be smaller without sustained therapy and broad coverage."
          ],
          discussion: [
            "Should future trials focus on primary prevention cohorts or on identifying maximal-benefit subphenotypes within secondary prevention?",
            "How do we quantify ‚Äònet cardiovascular benefit‚Äô in the presence of competing risks and polypharmacy?",
            "What policy and health-system levers matter most for population-level event reduction (coverage, adherence programs, monitoring)?"
          ],
          citations: [
            "Lincoff AM, et al. N Engl J Med. 2023;389:2221‚Äì2232. doi:10.1056/NEJMoa2307563."
          ]
        }
      }
    }
  ];

  // --- Consistent headings across levels ---
  const SECTION_ORDER = [
    { key: "tldr", title: "TL;DR" },
    { key: "bigQuestion", title: "The Big Question" },
    { key: "methods", title: "How they tested it (Methods)" },
    { key: "results", title: "What they found (Results)" },
    { key: "limitations", title: "Limitations & caveats" },
    { key: "discussion", title: "Discussion questions" },
    { key: "citations", title: "Citations" }
  ];

  // --- Elements ---
  const yearEl = document.getElementById("year");
  const homeView = document.getElementById("homeView");
  const detailView = document.getElementById("detailView");
  const paperListEl = document.getElementById("paperList");
  const searchInput = document.getElementById("searchInput");
  const homeBtn = document.getElementById("homeBtn");

  const paperTitleEl = document.getElementById("paperTitle");
  const paperMetaEl = document.getElementById("paperMeta");
  const paperTagsEl = document.getElementById("paperTags");
  const paperStatusEl = document.getElementById("paperStatus");
  const paperDateEl = document.getElementById("paperDate");

  const tabButtons = Array.from(document.querySelectorAll("[data-level]"));
  const panels = {
    beginner: document.getElementById("panel-beginner"),
    medium: document.getElementById("panel-medium"),
    pro: document.getElementById("panel-pro")
  };

  // --- Helpers ---
  function escapeHtml(str){
    return String(str)
      .replaceAll("&","&amp;").replaceAll("<","&lt;")
      .replaceAll(">","&gt;").replaceAll('"',"&quot;")
      .replaceAll("'","&#039;");
  }

  function setHash(id){
    // Keeps it static-site friendly: /#paper-id
    location.hash = id ? `#${id}` : "#";
  }

  function formatDate(iso){
    // Simple: YYYY-MM-DD ‚Üí MMM DD, YYYY (no localization needed for demo)
    const d = new Date(iso + "T00:00:00");
    const opts = { year:"numeric", month:"short", day:"2-digit" };
    return d.toLocaleDateString(undefined, opts);
  }

  function badgeTone(relevance){
    if (relevance === "Hot") return "good";
    if (relevance === "Trending") return "warn";
    return "good";
  }

  function renderPaperList(items){
    paperListEl.innerHTML = "";
    items.forEach(p => {
      const ev = p.evidenceBadge || { tone:"warn", text:"Evidence: ‚Äî" };
      const item = document.createElement("div");
      item.className = "paperItem";
      item.setAttribute("role","button");
      item.setAttribute("tabindex","0");
      item.setAttribute("aria-label", `Open paper: ${p.title}`);
      item.addEventListener("click", () => openPaper(p.id));
      item.addEventListener("keydown", (e) => {
        if (e.key === "Enter" || e.key === " ") openPaper(p.id);
      });

      item.innerHTML = `
        <div style="display:flex; justify-content:space-between; gap:10px; flex-wrap:wrap;">
          <div style="min-width:240px; flex:1;">
            <h3 class="paperTitle">${escapeHtml(p.title)}</h3>
            <p class="paperSub">
              ${escapeHtml(p.journal)} ‚Ä¢ ${escapeHtml(p.year)} ‚Ä¢ ${escapeHtml(p.area)}
            </p>
          </div>
          <div class="row" style="align-items:flex-start; justify-content:flex-end;">
            <span class="badge ${badgeTone(p.relevance)}">‚óè ${escapeHtml(p.relevance)}</span>
            <span class="badge ${escapeHtml(ev.tone)}">${escapeHtml(ev.text)}</span>
          </div>
        </div>
        <div class="row">
          ${p.tags.slice(0,4).map(t => `<span class="pill">${escapeHtml(t)}</span>`).join("")}
        </div>
      `;
      paperListEl.appendChild(item);
    });

    if (!items.length){
      paperListEl.innerHTML = `
        <div class="paperItem" style="cursor:default;">
          <h3 class="paperTitle">No matches</h3>
          <p class="paperSub">Try a different keyword (e.g., ‚ÄúOSA‚Äù, ‚ÄúT1D‚Äù, ‚ÄúGLP-1‚Äù, ‚ÄúAlzheimer‚Äôs‚Äù).</p>
        </div>
      `;
    }
  }

  function renderSections(level, paper){
    const data = paper.summaries[level];

    const kpiHtml = (data.kpi && data.kpi.length) ? `
      <div class="kpi">
        ${data.kpi.map(k => `
          <div class="box">
            <div class="label">${escapeHtml(k.label)}</div>
            <div class="value">${escapeHtml(k.value)}</div>
          </div>
        `).join("")}
      </div>
      <div class="divider"></div>
    ` : "";

    const sectionHtml = SECTION_ORDER.map(s => {
      const content = data[s.key] || [];
      const list = Array.isArray(content) ? content : [content];

      if (s.key === "citations"){
        return `
          <div class="section">
            <h2>${escapeHtml(s.title)}</h2>
            <ol class="list">
              ${list.map(li => `<li>${escapeHtml(li)}</li>`).join("")}
            </ol>
            ${paper.links?.length ? `
              <p class="small" style="margin-top:10px;">
                Links:
                ${paper.links.map(l => `<a href="${l.url}" target="_blank" rel="noreferrer">${escapeHtml(l.label)}</a>`).join(" ‚Ä¢ ")}
              </p>
            ` : ""}
          </div>
        `;
      }

      return `
        <div class="section">
          <h2>${escapeHtml(s.title)}</h2>
          <ul class="list">
            ${list.map(li => `<li>${escapeHtml(li)}</li>`).join("")}
          </ul>
        </div>
      `;
    }).join('<div class="divider"></div>');

    return kpiHtml + sectionHtml;
  }

  function setActiveLevel(level, paper){
    // Tabs ARIA
    tabButtons.forEach(btn => {
      const isSelected = btn.dataset.level === level;
      btn.setAttribute("aria-selected", isSelected ? "true" : "false");
    });

    // Panels
    Object.entries(panels).forEach(([k, el]) => {
      el.classList.toggle("hidden", k !== level);
      if (k === level){
        el.innerHTML = renderSections(level, paper);
      }
    });
  }

  function openPaper(id){
    const paper = PAPERS.find(p => p.id === id);
    if (!paper) return;

    // Switch views
    homeView.classList.add("hidden");
    detailView.classList.remove("hidden");

    // Header content
    paperTitleEl.textContent = paper.title;

    paperMetaEl.innerHTML = `
      <span>üßæ <strong>Journal:</strong> ${escapeHtml(paper.journal)}</span>
      <span>üìÖ <strong>Year:</strong> ${escapeHtml(paper.year)}</span>
      <span>üß™ <strong>Design:</strong> ${escapeHtml(paper.design)}</span>
      <span>üë• <strong>Sample:</strong> ${escapeHtml(paper.sample)}</span>
      <span>üè• <strong>Area:</strong> ${escapeHtml(paper.area)}</span>
    `;

    paperTagsEl.innerHTML = paper.tags.map(t => `<span class="pill">${escapeHtml(t)}</span>`).join("");

    const ev = paper.evidenceBadge || { tone:"warn", text:"Evidence: ‚Äî" };
    paperStatusEl.className = `badge ${badgeTone(paper.relevance)}`;
    paperStatusEl.textContent = `‚óè ${paper.relevance}`;

    paperDateEl.textContent = `Updated: ${formatDate(paper.updated)}`;

    // Default level
    setActiveLevel("beginner", paper);

    // Update hash
    setHash(paper.id);
  }

  function goHome(){
    detailView.classList.add("hidden");
    homeView.classList.remove("hidden");
    setHash(null);
  }

  function onHashRoute(){
    const id = (location.hash || "").replace("#","");
    if (!id){ goHome(); return; }
    const exists = PAPERS.some(p => p.id === id);
    if (exists) openPaper(id);
    else goHome();
  }

  // --- Events ---
  homeBtn.addEventListener("click", goHome);

  tabButtons.forEach(btn => {
    btn.addEventListener("click", () => {
      const id = (location.hash || "").replace("#","");
      const paper = PAPERS.find(p => p.id === id);
      if (!paper) return;
      setActiveLevel(btn.dataset.level, paper);
    });
  });

  // Keyboard shortcuts: 1/2/3 switch levels; Esc returns home
  document.addEventListener("keydown", (e) => {
    const inInput = e.target && (e.target.tagName === "INPUT" || e.target.tagName === "TEXTAREA");
    if (inInput) return;

    if (e.key === "Escape") { goHome(); return; }

    const id = (location.hash || "").replace("#","");
    const paper = PAPERS.find(p => p.id === id);
    if (!paper) return;

    if (e.key === "1") setActiveLevel("beginner", paper);
    if (e.key === "2") setActiveLevel("medium", paper);
    if (e.key === "3") setActiveLevel("pro", paper);
  });

  // Search filter on Home
  function applySearch(){
    const q = (searchInput.value || "").trim().toLowerCase();
    if (!q){ renderPaperList(PAPERS); return; }

    const filtered = PAPERS.filter(p => {
      const hay = [
        p.title, p.journal, p.year, p.design, p.sample, p.area,
        ...(p.tags || [])
      ].join(" ").toLowerCase();
      return hay.includes(q);
    });
    renderPaperList(filtered);
  }
  searchInput.addEventListener("input", applySearch);

  // Router
  window.addEventListener("hashchange", onHashRoute);

  // Init
  yearEl.textContent = new Date().getFullYear();
  renderPaperList(PAPERS);
  onHashRoute();
</script>
</body>
</html>
